Search - tctmd.com

Displaying 581 - 600 of 674

Sort: Relevancy | Date

News Daily News

Signs Point to Relationship Between Clopidogrel Efficacy, Cigarette Smoking

Yael L. Maxwell

June 20, 2012

News Daily News

Subestudio PLATO: Los Pacientes con SCA y Antecedentes de ACV no están en Desventaja con el Ticagrelor

Yael L. Maxwell

June 01, 2012

News Daily News

PLATO Substudy: ACS Patients with Prior Stroke at No Disadvantage with Ticagrelor

Yael L. Maxwell

June 01, 2012

News Daily News

CREDO-Kyoto Published: Extended DAPT Appears to Raise Bleeding Without Curbing Ischemic Events

L.A. McKeown

June 01, 2012

News Daily News

GIFT Published: Role of CYP2C19 in Clopidogrel Response Variability Confirmed

L.A. McKeown

May 23, 2012

News Daily News

Switching to Non-CYP3A4-Metabolized Statins May Reduce High Platelet Reactivity

April 25, 2012

News Daily News

Cambiar a Estatinas No Metabolizadas por CYP3A4 podría Reducir la Alta Reactividad Plaquetaria

April 25, 2012

Presentation GI2 2012

Dual Antiplatelet Therapy Post PCI: Challenging the Guidelines

Presenter: Fausto Feres

April 13, 2012

News Daily News

JAMA Letters Continue Debate Over Genotype, Clopidogrel Response

Caitlin E. Cox

April 12, 2012

News Daily News

CHARISMA Genetics Analysis: CYP2C19 Variants Show Little Clinical Impact

April 10, 2012

News Daily News

Se Publica el PRODIGY: No se observa Ventaja alguna a Largo Plazo con el Clopidogrel

April 03, 2012

News Daily News

PRODIGY Published: No Advantage to Long-term Clopidogrel

April 03, 2012

Presentation

Short- vs. Long-term Duration of Dual Antiplatelet Therapy (DAPT) After Coronary Stenting

Presenter: Marco Valgimigli

April 02, 2012

News Daily News

Rapid Bedside Genotyping May Help Guide Antiplatelet Strategy After PCI

Caitlin E. Cox

March 30, 2012

News Daily News

El Genotipado Rápido a Pie de Cama podría Determinar la Estrategia Antiplaquetaria tras una PCI

Caitlin E. Cox

March 30, 2012

News Conference News ACC 2012

EXOME: New Genetic Sequencing Zeroes in on Clopidogrel Response Variants

March 25, 2012

Presentation ACC 2012

A New Strategy for Discontinuation of Dual Antiplatelet Therapy: Real Safety and Efficacy of 3-Month Dual Antiplatelet Therapy Following Zotarolimus-Eluting Stent Implantation: RESET Trial

Presenter: Myeong-Ki Hong

March 25, 2012

News Conference News ACC 2012

Three Months of Antiplatelet Therapy with Endeavor Equal to 1 Year with Other DES

Jason Kahn

March 24, 2012

News Conference News ACC 2012

Prasugrel Effective in Stable Patients With Poor Response to Clopidogrel

Jason Kahn

March 24, 2012

News Daily News

Better Clopidogrel Response Seen with Increased Smoking Levels

Jason Kahn

March 21, 2012

Advertisement

Signs Point to Relationship Between Clopidogrel Efficacy, Cigarette Smoking

Subestudio PLATO: Los Pacientes con SCA y Antecedentes de ACV no están en Desventaja con el Ticagrelor

PLATO Substudy: ACS Patients with Prior Stroke at No Disadvantage with Ticagrelor

CREDO-Kyoto Published: Extended DAPT Appears to Raise Bleeding Without Curbing Ischemic Events

GIFT Published: Role of CYP2C19 in Clopidogrel Response Variability Confirmed

Switching to Non-CYP3A4-Metabolized Statins May Reduce High Platelet Reactivity

Cambiar a Estatinas No Metabolizadas por CYP3A4 podría Reducir la Alta Reactividad Plaquetaria

Dual Antiplatelet Therapy Post PCI: Challenging the Guidelines

JAMA Letters Continue Debate Over Genotype, Clopidogrel Response

CHARISMA Genetics Analysis: CYP2C19 Variants Show Little Clinical Impact

Se Publica el PRODIGY: No se observa Ventaja alguna a Largo Plazo con el Clopidogrel

PRODIGY Published: No Advantage to Long-term Clopidogrel

Short- vs. Long-term Duration of Dual Antiplatelet Therapy (DAPT) After Coronary Stenting

Rapid Bedside Genotyping May Help Guide Antiplatelet Strategy After PCI

El Genotipado Rápido a Pie de Cama podría Determinar la Estrategia Antiplaquetaria tras una PCI

EXOME: New Genetic Sequencing Zeroes in on Clopidogrel Response Variants

A New Strategy for Discontinuation of Dual Antiplatelet Therapy: Real Safety and Efficacy of 3-Month Dual Antiplatelet Therapy Following Zotarolimus-Eluting Stent Implantation: RESET Trial

Three Months of Antiplatelet Therapy with Endeavor Equal to 1 Year with Other DES

Prasugrel Effective in Stable Patients With Poor Response to Clopidogrel

Better Clopidogrel Response Seen with Increased Smoking Levels

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content